Trial Profile
A Study on Optimizing HBeAg Seroconversion in HBeAg Positive CHB Patients With Combination or Sequential Treatment of Pegylated Interferon Alpha-2a and Entecavir
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Entecavir
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms OSST
- Sponsors Roche
- 13 Nov 2012 Primary endpoint 'Seroconversion-rate' has been met.
- 06 Jul 2012 Actual patient number changed from 134 to 200 as reported by ClinicalTrials.gov.
- 18 Apr 2012 Actual patient number changed from 119 to 134 as reported by ClinicalTrials.gov.